1. Overview of genotoxic impurities in pharmaceutical development;Bercu;Int. J. Toxicol.,2009
2. European Medicines Agency Evaluation of Medicines for Human Use, Guideline on the Limits of Genotoxic Impurities 2006
3. Genotoxic and Carcinogenic Impurities in Drug Substances and Products, Recommended Approaches, US FDA, Guidance for Industry 2008
4. Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk, ICH guidelines M7 2014
5. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes;Eckhardt;J. Med. Chem.,2007